Bluejay Diagnostics, Inc.

BJDX Nasdaq SEC CIK 1704287
Follow Bluejay Diagnostics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$2M −25.9% vs same quarter last year
EPS, diluted −$1.72
Operating cash flow −$2M −47.3% vs same quarter last year
Operating income −$2.1M −27.5% vs same quarter last year
Net income by quarter
−$1.4M
−$1.9M
−$2M
−$1.6M
−$1.4M
−$1.9M
−$2.3M
−$2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$10M−$7.5M−$5M−$2.5M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$6.8M
FY24−$7.7M
FY23−$10M
FY22−$9.3M
FY21−$3.5M
FY20−$1.2M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$10M−$7.5M−$5M−$2.5M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$6.2M
FY24−$8.1M
FY23−$9M
FY22−$8.9M
FY21−$4.4M
FY20-
FY19-